Glaxosmithkline Intellectual Property Development Limited

Abbisko Therapeutics Co., Ltd

Glaxo Group Limited

Baowei Zhao

Feng Ren

Mingming Zhang

Hongping Yu

Yaochang Xu

Zhui Chen

Yingxia Sang

Qian Liu

Xiao Ding

Weiqiang Xing

Yang Zhan

Zehong Wan

Xichen Lin

Luigi Piero Stasi

Jose Luis Castro Pineiro

David Robert Vesey

Hailong Wang

Yun Jin

Colin Michael Edge

Yongxian Zhang

Shuqun Yang

Guanghui Deng

Kevin Meng

A biphenyl fluorine double bond derivative having a structure as represented by formula (I), a preparation method therefor, and a pharmaceutical application thereof. The biphenyl fluorine double bond derivative having the structure as represented by formula (I) can be widely applied in the preparation of medicaments for preventing and/or treating cancers or tumors, immune-related diseases and disorders, communicable diseases, infectious diseases or metabolic diseases mediated by PD-1/PD-L1 signal pathways, and is expected to be developed into a new generation of PD-1/PD-L1 inhibitors.

Biphenyl fluorine double bond derivative, preparation method therefor, and pharmaceutical application thereof

This application describes a nitrogen heteroaryl derivative having CSF1R inhibitory activity, and a preparation method therefor and an application thereof. Compounds in the present invention has a structure represented by formula (I) as below, and the definition on substituents is as stated in the description and the claims. The compounds in the this application can be widely applied to preparation of drugs for treating cancer, tumor, autoimmune disease, metabolic disease, or metastatic disease, in particular ovarian cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, glioblastoma, multiple myeloma, metabolic disease, neurodegenerative disease, metastasis of primary tumor sites, or osseous metastatic cancer, and a new generation of CSF1R inhibitor drugs is expected to be developed. 

Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof

An N-(azaaryl)cyclolactam-1-carboxamide derivative having a structure of formula (I), a preparation method therefor, and a use thereof are disclosed in the application. Each substituent are defined in the specification and claims. The series of compounds of the application can be widely applied in the preparation of drugs for treating cancer, tumor, autoimmune disease, metabolic disease or metastatic disease, particularly for treating ovarian cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, glioblastoma, multiple myeloma, metabolic disease, neurodegenerative disease, primary tumor site metastasis or osseous metastasis cancer, and are expected to be developed into a new generation of CSF-1R inhibitor drugs. 

N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof

An azaaryl derivative with the structure of formula (I), a preparation method therefor and a pharmaceutical use thereof are disclosed in this application. The series of compounds of the this application can be widely applied in the preparation of drugs for treating cancer, tumor, autoimmune disease, metabolic disease or metastatic disease, particularly for treating ovarian cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, glioblastoma, multiple myeloma, metabolic disease, neurodegenerative disease, primary site tumor metastasis or osseous metastasis cancer, and are expected to be developed into a new generation of CSF-1R inhibitor drugs. 

Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy

Compounds of Formula (I) or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising these compounds, the use of these compounds and compositions in the treatment of diseases in which LRRK-2 kinase is involved. 

Compounds for inhibiting LRRK2 kinase activity

Disclosed are substituted fused pyrazoles, for example substituted indazoles, that inhibit LRRK2 kinase activity, pharmaceutical compositions containing them and their use in the treatment of Parkinson's disease.

Substituted fused pyrazole compounds and their use as LRRK2 inhibitors

Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

Compounds

The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

LRRK2 inhibitors for the treatment of Parkinson's disease

The present invention relates to novel compounds having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.

Heterocyclic compounds

The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.

Growing community of inventors

Shanghai, China

Baowei Zhao